Non-Covalent BTK Drug Wins Broad Approval in Most Common Leukemia

MedPage TodayView source article

Part of story

Pirtobrutinib wins FDA approval for frontline CLL/SLL treatment

The FDA expanded approval of pirtobrutinib, a non-covalent BTK inhibitor, for chronic lymphocytic leukemia and small lymphocytic lymphoma in the frontline setting.

Oct 2, 20262 sourcesFDA drug approval Cancer treatment breakthroughs

Pirtobrutinib wins FDA approval for frontline CLL/SLL treatment

Other sources for this story

The American Journal of Managed Care

Non-Covalent BTK Drug Wins Broad Approval in Most Common Leukemia

Part of story

Pirtobrutinib wins FDA approval for frontline CLL/SLL treatment

Other sources for this story

FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion

Non-Covalent BTK Drug Wins Broad Approval in Most Common Leukemia

Part of story

Pirtobrutinib wins FDA approval for frontline CLL/SLL treatment

Other sources for this story

FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion